Activating mutations of KRAS and deactivating mutations of TP53 and SMAD4 are also common in CRC, and their sequential accumulation contributes to the adenoma-carcinoma sequence of disease progression [5]. This evidence concerns the gene TP53 and colorectal carcinoma.